FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Ddog Crushes Expectations As Growth Continues To Accelerate

作者

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

DDOG crushed Q1 expectations with revenue of $1.006B (+32% Y/Y), beating guidance and consensus by approximately $50M, while non-GAAP EPS of $0.60 exceeded Street estimates by $0.09. Large customer growth meaningfully reaccelerated with $100K+ ARR customers growing 21% Y/Y to approximately 4,550, up from 19% in Q4, validating the platform consolidation thesis as enterprises increasingly consolidate observability and security workloads. Management substantially raised FY 26 guidance with revenue now expected at $4.30B-4.34B (vs. prior $4.06B-4.10B and consensus $4.12B), representing 25% growth at midpoint. We believe the strong operational leverage is evident with non-GAAP operating margin expanding 30 bps to 22% despite heavy AI investments. The company's robust $4.8B cash position provides substantial firepower for strategic investments in the rapidly evolving AI infrastructure landscape, while 29% FCF margin demonstrates efficient scaling capabilities.

相关文章

Insider Trading

根据最近提交给美国证券交易委员会(SEC)的文件显示,康斯坦利姆公司内部人士出售了价值822,057美元的股票。

2026年5月5日,执行副总裁兼首席财务官郭杰克(Jack Q. Guo)出售了Constellium (CSTM)的25,201股股票,套现822,057美元。根据向美国证券交易委员会(SEC)提交的4号表格文件,郭杰克目前控制着该公司共计185,368股普通股,其中185,368股为直接持有。 SEC文件链接: https://www.sec.gov/Archives/edgar/data/1563411/000209518226000002/xslF345X05/wk-form4_1778162530.xmlPrice: $33.06, Change: $-0.27, Percent Change: -0.83%

$CSTM
Asia

最新消息:武汉益智生物制药有限公司(隶属于中国生物制药集团)的腹水药物申请已获中国受理。

(更新内容包括该药物的主要研发方武汉益智生物制药) 武汉益智生物制药(港交所代码:2496)与中国生物制药(港交所代码:1177)旗下子公司共同研发的药物M701的新药申请已获中国国家药品监督管理局受理。 根据周四在香港交易所提交的两份文件显示,该药物用于治疗晚期上皮恶性肿瘤引起的恶性腹水。 中国生物制药旗下子公司正泰天青药业集团于2024年8月获得该药物在中国大陆的独家可转授许可,负责该药物的注册、研发、生产和销售。

$HKG:1177$HKG:2496
International

3月份美国建筑支出增幅超出预期,住宅建设增加

美国3月份建筑支出增长0.6%,高于彭博社此前调查预测的0.2%的增幅,而2月份则下降了0.2%。 私人住宅建设增长1.7%,其中独栋住宅建设增长2.7%,多户住宅建设增长0.3%,房屋改造增长0.9%。 私人非住宅建设和公共建设均下降0.2%。